A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charlene Mantia, Glenn J. Hanna, Yohann Loriot, Peter Vu, Diego Tosi, Tudor-Eliade Ciuleanu, Abhishek Tripathi, Pamela N. Munster, Aarti K. Bhatia, Lauren Shih, Andrea Zivi, Ik Shin Chin, M. Julia Lostes-Bardaji, Frederic Rolland, Ivan Barrera, Kurt Preugschat, Paola M. Grant, Ian Hodgson, Cesar Augusto Perez, Ari J. Rosenberg
Institutions: Harvard University, Dana-Farber Cancer Institute, Université Paris-Saclay, Institut Gustave Roussy, University of California San Diego, Institut Regional du Cancer de Montpellier, City Of Hope National Medical Center, University of California, San Francisco, Yale Cancer Center, University of Washington, Fred Hutch Cancer Center, Azienda Ospedaliera Universitaria Integrata Verona, Clatterbridge Cancer Centre NHS Foundation Trust, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut de Cancérologie de l'Ouest, Precision for Medicine (United States), Corbus Pharmaceuticals (United States), University of Chicago
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162518927
Cites:
Cited by:
Related to: